Shattuck Labs
NASDAQ: STTKAustin, US · Founded 2016 · Delaware corporation · 5 known investors
Find your way into Shattuck Labs
Shattuck Labs is a biotechnology company developing biologic medicines targeting TNF receptors, including the TL1A/DR3 axis, for patients with cancer and inflammatory or life-altering diseases. It is built around proprietary protein-engineering platforms and a pipeline of immunotherapy drug candidates.
Founders & leadership
Shattuck Labs was founded in 2016 by Josiah Hornblower and Taylor.
JH
Josiah HornblowerinCo-founder · Executive Chairman2020–2021
T
TaylorCo-founder & Chief Executive Officer, Board Member
Board
WL
Walter LoewenbaumBoard director
Investors · 5
Reported raises · per SEC filings
Form D private placements$165.4M disclosed across 5 of 6 rounds · 2016–2026
▶$83MraisedJun 2020 · 32 investors · BiotechnologyRule 506(b)
▶$83MraisedJun 2020 · 32 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- G. Walter LoewenbaumDirector
- Taylor SchreiberExecutive Officer, Director
- Charles DorranceDirector
- Victor StoneDirector
- Josiah HornblowerDirector
- George GolumbeskiDirector
- Mike LeeDirector
- Neil GibsonDirector
- Tyler BrousDirector
- Offering amount
- $83M
- Amount sold
- $83M
- First sale
- Jun 2020
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$25.4MraisedFeb 2020 · 71 investors · BiotechnologyRule 506(b)
▶$25.4MraisedFeb 2020 · 71 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Taylor SchreiberExecutive Officer, Director
- Josiah HornblowerExecutive Officer, Director
- G. Walter LoewenbaumDirector
- Tyler BrousDirector
- Chris HurffDirector
- Neil GibsonDirector
- Charles DorranceDirector
- George GolumbeskiDirector
- David G. LoweDirector
- Offering amount
- $50M
- Amount sold
- $25.4M
- First sale
- Jan 2020
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$46.6MraisedMay 2018 · 62 investors · BiotechnologyRule 506(b)
▶$46.6MraisedMay 2018 · 62 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Taylor SchreiberExecutive Officer, Director
- Tyler BrousDirector
- Josiah HornblowerExecutive Officer, Director
- Charles DorranceDirector
- Charles GolumbeskiDirector
- David G. LoweExecutive Officer, Director
- G. Walter LoewenbaumDirector
- Neil GibsonDirector
- Offering amount
- $47.3M
- Amount sold
- $46.6M
- First sale
- May 2018
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$7MraisedApr 2017 · 27 investors · BiotechnologyRule 506(b)
▶$7MraisedApr 2017 · 27 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- G. Walter LoewenbaumDirector
- Tyler BrousDirector
- Taylor SchreiberExecutive Officer, Director
- Neil GibsonDirector
- David G. LoweDirector
- Josiah HornblowerExecutive Officer, Director
- Offering amount
- $7M
- Amount sold
- $7M
- First sale
- Mar 2017
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$3.4MraisedAug 2016 · 25 investors · BiotechnologyRule 506(b)
▶$3.4MraisedAug 2016 · 25 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Walter LoewenbaumDirector
- Josiah HornblowerExecutive Officer, Director
- Offering amount
- $3.5M
- Amount sold
- $3.4M
- First sale
- Jul 2016
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$679.4Mvaluation at IPOOct 2020 · $17.00/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Competitors · 3
by search overlap
Seeking Alpha16 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Eli Lilly13 shared keywordsEli Lilly discovers, develops, manufactures, and markets human pharmaceutical products across cardiometabolic, oncology, immunology, and neuroscience therapeutic areas, selling to healthcare providers and patients in approximately 90 countries through wholesalers, direct sales representatives, and digital platforms.
Dialectic Therapeutics12 shared keywordsDialectic Therapeutics is a clinical-stage biotechnology company developing anti-cancer drugs using its Antiapoptotic Protein Targeted Degradation (APTaD) platform, which induces cancer cells to degrade proteins such as BCL-XL. Its lead candidate, DT2216, is in Phase 1/2 trials for fibrolamellar carcinoma and platinum-resistant ovarian cancer.
Companies competing with Shattuck Labs for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights - BioSpacebiospace.com · Aug 2026
Shattuck Labs Q2 Earnings: $15.2M Net Loss | STTK Stock Newsstocktitan.net · Aug 2026Frequently asked questions
- What does Shattuck Labs do?
- Shattuck Labs is a biotechnology company developing biologic medicines targeting TNF receptors, including the TL1A/DR3 axis, for patients with cancer and inflammatory or life-altering diseases. It is built around proprietary protein-engineering platforms and a pipeline of immunotherapy drug candidates.
- Who founded Shattuck Labs?
- Shattuck Labs was founded by Josiah Hornblower, Taylor in 2016.
- Who are Shattuck Labs's investors?
- Shattuck Labs's investors include EcoR1 Capital, Hatteras Venture Partners, OrbiMed, REDMILE, T. Rowe Price.
- How much funding has Shattuck Labs raised?
- Shattuck Labs has disclosed $165.4M raised across 5 of its 6 known rounds.
- Where is Shattuck Labs headquartered?
- Shattuck Labs is headquartered in Austin, US.